Kaleido Biosciences, Inc.

OTCPK:KLDO Stock Report

Market Cap: US$4.3k

Kaleido Biosciences Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenure7.4yrs

Recent management updates

Analysis Article • Dec 14

Are Insiders Buying Kaleido Biosciences, Inc. (NASDAQ:KLDO) Stock?

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

Recent updates

Analysis Article • Feb 09

Is Kaleido Biosciences, Inc. (NASDAQ:KLDO) Popular Amongst Insiders?

If you want to know who really controls Kaleido Biosciences, Inc. ( NASDAQ:KLDO ), then you'll have to look at the...
Analysis Article • Dec 14

Are Insiders Buying Kaleido Biosciences, Inc. (NASDAQ:KLDO) Stock?

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

CEO

Kaleido Biosciences has no CEO, or we have no data on them.

Board Members

NamePositionTenureCompensationOwnership
Theodose Melas-Kyriazi
Independent Chairperson of the Board6.9yrsUS$146.56kno data
Laurie Glimcher
Member of Scientific Advisory Board7.4yrsno datano data
C. Kahn
Member of Scientific Advisory Board7.4yrsno datano data
Anthony Quinn
Independent Director10.3yrsUS$124.73kno data
Laura Kiessling
Member of Scientific Advisory Board7.4yrsno datano data
Fergus Shanahan
Chairman of Scientific Advisory Board6.8yrsno datano data
Max Nieuwdorp
Member of Scientific Advisory Board7.4yrsno datano data
Peter Turnbaugh
Member of Scientific Advisory Board7.4yrsno datano data
Robert Jenq
Member of Scientific Advisory Board7.4yrsno datano data
7.4yrs
Average Tenure
67yo
Average Age

Experienced Board: KLDO's board of directors are considered experienced (7.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/20 12:00
End of Day Share Price 2026/06/17 00:00
Earnings2021/12/31
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kaleido Biosciences, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Taylor FeehleyChardan Capital Markets, LLC
Keay NakaeChardan Capital Markets, LLC
Gbolahan Amusa BenzChardan Capital Markets, LLC